•Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds
•Author's response to the editorial commentary, "TL1A and DR3 in IBD: from mucosal immunopathology to a new era of targeted therapy"
•The burden and unique patterns of extraintestinal manifestations in Chinese inflammatory bowel disease: a nationwide multicenter investigation
•Nano-Backpack Engineered Probiotics with Reactive Oxygen Species-Responsive Tungsten Release for Synergistic Therapy of Inflammatory Bowel Disease
•The gut microbiota-enteric nervous system axis: from bidirectional programming to precision therapeutics in digestive diseases
